• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling.
 
DeviceLacrosse NSE ALPHA Coronary Dilatation Catheter
Generic NameCatheter, percutaneous transluminal coronary angioplasty (ptca), cutting/scoring
ApplicantNIPRO VASCULAR CORPORATION (formerly Goodman Co., Ltd.)
5f Kdx Nagoya Sakae Bldg., 4-5-3
Sakae, Naka-Ku
Nagoya 
PMA NumberP230026
Date Received08/31/2023
Decision Date06/06/2024
Product Code NWX 
Advisory Committee Cardiovascular
Clinical TrialsNCT04985773
Expedited Review Granted? No
Combination ProductNo
Predetermined Change Control Plan AuthorizedNo
Approval Order Statement  
The Lacrosse NSE ALPHA Coronary Dilatation Catheter is device is indicated for balloon dilatation of the stenotic portion of the coronary artery including both de novo and in-stent restenosis, for the purpose of improving myocardial perfusion.
Approval OrderApproval Order
SummarySummary of Safety and Effectiveness
LabelingLabeling
Post-Approval StudyShow Report Schedule and Study Progress
Supplements:  S001 S003 S004 S005 
-
-